research use only

Piroxicam COX inhibitor

Name: Piroxicam
Brand: Selleck Chemicals
SKU: S1713
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S1713

Piroxicam (CP 16171) is a non-selective COX inhibitor, used in the treatment of rheumatoid and osteoarthritis.

Chemical Structure

Molecular Weight: 331.35

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 100%

100

Related Targets	Adrenergic Receptor AChR 5-HT Receptor Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel GluR MAO Beta Amyloid NMDAR P2 Receptor Trk receptor Serotonin Transporter Notch Cannabinoid Receptor P-gp CaMK Opioid Receptor BACE Sigma Receptor FAAH Neurokinin Receptor OX Receptor CGRP Receptor BChE Adenosine Deaminase CCK receptor MT Receptor
Related Products	NS-398 (NS398) Paeoniflorin (NSC 178886) Lumiracoxib Xanthohumol Bufexamac Oroxin B Tolfenamic Acid Nimesulide Ginsenoside Rd Indometacin Sodium Pranoprofen (-)-Epicatechin gallate Salicin SC-560 Triflusal Phenacetin (+/-)-Sulfinpyrazone (+)-Catechin hydrate Niflumic acid Etoricoxib 4-Hydroxyphenylpyruvic acid 3-Carene Rutaecarpine Fenbufen Licofelone (ML3000)

Chemical Information, Storage & Stability

Molecular Weight	331.35	Formula	C₁₅H₁₃N₃O₄S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	36322-90-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	CP 16171			Smiles	CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3

Solubility

In vitro
Batch:

DMSO : 66 mg/mL ( (199.18 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.3mg/ml (9.96mM)	Taking the 1 mL working solution as an example, add 50 μL of 66 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.47mg/ml (1.42mM)	Taking the 1 mL working solution as an example, add 50 μL of 9.4 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	COX ^[1]
In vitro	Piroxicam induces activation of extracellular signal-regulated kinase (ERK) in neurones and phosphorylation of heavy molecular weight neurofilaments, cytoskeletal substrates of ERK in rat spinal cord cultures. This compound and NS-398 protect neurones against hypoxia/reperfusion in rat spinal cord cultures. ^[1]
In vivo	Piroxicam at doses higher than 0.04%, strongly inhibits the development of GST-P-positive and neoplastic nodules as well as fibrosis, cirrhosis and formation of 8-hydroxydeoxyguanosine (8-OHdG) adducts in rats. ^[2] This compound increases the expression of all three MHC antigens compared to either control or azoxymethane (AOM)-treated rats. It up-regulates colonic MHC antigen expression in the AOM model of colonic carcinogenesis. ^[3] This chemical combined with Cisplatin has antitumor activity against oral malignant melanoma (OMM) and oral squamous cell carcinoma (SCC) in rats. ^[4] It inhibits prostaglandin synthesis through cyclooxygenase blockade in dog, and does not have any direct cytotoxic effects in vitro. ^[5] It also binds strongly to plasma proteins and could stop Ochratoxin A (OTA) -binding and transport into target organs, thereby preventing its nephrotoxicity in rats. This agent prevents the enzymuria induced by OTA and increases renal elimination of OTA in rats. ^[6]
References	https://pubmed.ncbi.nlm.nih.gov/11208911/ https://pubmed.ncbi.nlm.nih.gov/9364001/ https://pubmed.ncbi.nlm.nih.gov/7835954/ https://pubmed.ncbi.nlm.nih.gov/14765798/ https://pubmed.ncbi.nlm.nih.gov/11394830/ https://pubmed.ncbi.nlm.nih.gov/7825181/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02253446	Completed	Primary Dysmenorrhea	Pamukkale University	May 2013	Phase 4
NCT01320709	Completed	Contraception Postcoital	Bayer	March 2011	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):